Scottsdale Research Institute (SRI) is currently conducting an FDA- and DEA-authorized Phase 2 clinical research study of medical cannabis (marijuana) for Post-traumatic Stress Disorder (PTSD) in military veterans.
The study is sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit that researches therapeutic applications for psychoactive substances such as cannabis and MDMA.
On March 14, 2014, the U.S. Public Health Service approved our study of smoked whole plant (botanical) marijuana for symptoms of PTSD in U.S. veterans. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. On December 17, 2014, MAPS was awarded a $2 million grant from the Colorado Department of Public Health and Environment to complete the study. The study has received authorization from the FDA, DEA, and Institutional Review Boards (IRBs), and began screening participants in January 2017 at our clinic in Phoenix, Arizona. Participants must be U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after trying either medication or psychotherapy.
The full study protocol can be found here (link to web version of protocol).